SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc . (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences. Details on the Company's participation are as follows: Event: 2025 Wells Fargo... Read More

Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million ; Adjusted EBITDA Increased 65% YOY to $226 million ; GAAP Diluted EPS Increased 85% YOY to $1.33 ; Non-GAAP Diluted EPS Increased 69% YOY to $1.54 1 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,275 - $1,355 million , Representing YOY Growth of 26% - 33%,... Read More

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO , July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX... Read More

SAN DIEGO , July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, August 5, 2025 , following the close of trading. Halozyme will host a conference call on Tuesday, August 5, 2025 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration... Read More

SAN DIEGO , June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000 ® Index, effective after market close on June 27 th , as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000 ® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by... Read More

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO , June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human... Read More

SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences. Details on the Company's participation are as follows: Event: Benchmark 2025 Healthcare House Call Virtual Conference Format: 1x1 Meetings Date: Thursday, May... Read More

Opdivo ® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new Opdivo ® (nivolumab) subcutaneous formulation developed with ENHANZE ® , Halozyme's proprietary recombinant human hyaluronidase enzyme... Read More

Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million ; Adjusted EBITDA Increased 40% YOY to $162 million ; GAAP Diluted EPS Increased 55% YOY to $0.93 ; non-GAAP Diluted EPS Increased 41% YOY to $1.11 1 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million ,... Read More

SAN DIEGO , May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET . A live audio webcast will be available on the Investor Relations section of the... Read More

SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025 , following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via... Read More

European Commission (EC) decision on marketing authorization application expected within approximately two months SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending European Commission (EC) approval of VYVGART® 1000mg... Read More

Complaint filed in New Jersey alleges Merck uses Halozyme's patented MDASE technology to develop SC Keytruda Halozyme is seeking damages and injunctive relief to stop the infringement SAN DIEGO , April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today filed a patent infringement lawsuit... Read More

SAN DIEGO , April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive... Read More

Subcutaneous DARZALEX ® is co-formulated with Halozyme's ENHANZE ® drug delivery technology SAN DIEGO , April 9, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval for an indication extension of DARZALEX ® (daratumumab) subcutaneous (SC) co-formulated with ENHANZE ® in the... Read More

SAN DIEGO , April 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) marketing authorization of the subcutaneous (SC) formulation of RYBREVANT ® (amivantamab), in combination with LAZCLUZE ® (lazertinib), for the first-line treatment of adult patients with advanced non-small cell... Read More

A decision on the European marketing authorization extension for the subcutaneous formulation of Opdivo is expected by June 2, 2025 SAN DIEGO , March 31, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of a new... Read More

SAN DIEGO , Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference. The presentation is scheduled for Wednesday, March 5 at 8:50am PT / 11:50am ET . A live audio webcast will be available on the Investor Relations section of the... Read More

Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million ; Adjusted EBITDA Increased 61% YOY to $196 million ; GAAP EPS Increased 63% YOY to $1.06 ; non-GAAP EPS Increased 54% YOY to $1.26 1 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance... Read More

SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025 , following the close of trading. Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The conference call may be accessed live... Read More

SAN DIEGO , Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorisation for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in... Read More

Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million , Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million , Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35 , Representing YoY Growth of 21% - 30% 1,2 Announces New $250 million Accelerated Share... Read More

SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025 , at 5:30 a.m. PT / 8:30 a.m. ET . On the call, Dr. Helen Torley , President and Chief Executive Officer, and Nicole LaBrosse , Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year... Read More

SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA ® [Immune Globulin Infusion 10% (Human) with Halozyme's Recombinant Human Hyaluronidase] by the Japanese Ministry of Health, Labour and Welfare (MHLW) for patients with agammaglobulinemia or hypogammaglobulinemia, disorders characterized by very low or absent... Read More

SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE ® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was... Read More

Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for... Read More

SAN DIEGO , Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follows: Event: Piper Sandler 36 th Annual Healthcare Conference Presenter: Nicole LaBrosse, Chief Financial Officer Format: Fireside Chat... Read More

SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. Helen Torley , president and chief executive officer of Halozyme , shared the following statement: "We continue to believe... Read More

Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close... Read More

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec... Read More

Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.27 1 Raised 2024 Financial Guidance Ranges for Total Revenue of $970 - $1,020 million , Representing YOY Growth of 17%-23%, Adjusted... Read More

Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO ® and SC through 2032 Reiterates 2024 Royalty Revenue Guidance of $520 -555 million and Expectations to Generate > $1 billion in 2027 Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT / 8:30am ET SAN DIEGO , Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision... Read More

SAN DIEGO , Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024 , following the close of trading. Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The conference call may be accessed live with... Read More

Four new targets nominated for total of six nominated targets, including FcRn (VYVGART ® Hytrulo), for ENHANZE ® drug delivery technology Halozyme to receive total upfront payment of $30 million for exclusive rights to targets SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and license agreement that... Read More

OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO , Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) with Halozyme's ENHANZE® drug delivery technology for the treatment... Read More

FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy SAN DIEGO , Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs) with Halozyme's ENHANZE® drug delivery technology. Tecentriq Hybreza™ can be injected subcutaneously... Read More

SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow: Event: 2024 Wells Fargo Healthcare Conference... Read More

Total Revenue of $231 million ; Net Income of $93 million ; Adjusted EBITDA of $137 million ; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.91 1 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus ® SC in Europe and the UK and VYVGART ® Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 - $1,015 million , Representing YOY Growth of... Read More

SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating results on Tuesday, August 6, 2024 , following the close of trading. Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration... Read More

OCREVUS® subcutaneous (SC) injection offers a new 10-minute administration with comparable efficacy and safety to intravenous (IV) infusion Provides an additional treatment option without the need for IV facilities, expanding accessibility for patients SAN DIEGO , June 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing... Read More

VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as a subcutaneous injection, approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) CIDP is the second FDA-approved indication for VYVGART® Hytrulo with ENHANZE® SAN DIEGO , June 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug... Read More

Company Granted New European Patent for ENHANZE ® Drug Delivery Platform SAN DIEGO , June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE ® rHuPH20 product obtained from Halozyme's ENHANZE ®... Read More

Conference Call Scheduled for Thursday, June 6 at 5:30am PT / 8:30am ET SAN DIEGO , June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of... Read More

SAN DIEGO , June 4, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, will present and host investor meetings at the Goldman Sachs 45 th Annual Global Healthcare conference. The presentation is scheduled for Tuesday, June 11 at 6:20 a.m. PT / 9:20 a.m. ET . A live audio webcast will be available on the Investor Relations... Read More

Updated Prescription Drug User Fee Act goal date of December 29, 2024 SAN DIEGO , May 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous formulation of Opdivo ® (nivolumab) co-formulated with... Read More

SAN DIEGO , May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse , Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences: Event: The Citizens JMP Life Sciences Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Tuesday, May 14, 2024 Presentation Time: 7:00 a.m. PT / 10:00 a.m. ET... Read More

Revenue Increased 21% YOY to $196 million ; Net Income of $77 million ; Adjusted EBITDA of $116 million ; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance: Total Revenue of $915 - $985 million , Representing YOY Growth of 10% - 19%, Adjusted EBITDA of $535 - $585 million , Representing YOY Growth of 26% - 37% and Non-GAAP... Read More

SAN DIEGO , April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan , M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley... Read More

SAN DIEGO , April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024 , following the close of trading. Halozyme will host a conference call on Tuesday, May 7, 2024 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via... Read More

SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences: Event: TD Cowen 44 th Annual Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Tuesday, March 5, 2024 Presentation Time: 11:50 a.m.... Read More

Reiterating 2024 Financial Guidance: Total Revenue of $915 -985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535 -585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted EPS of $3.55 -3.90, Representing YOY Growth of 28-41% Fourth Quarter Revenue Increased 27% YOY to $230 million ; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.82 1 Full Year 2023 Revenue Increased 26% YOY to $829... Read More

SAN DIEGO , Feb. 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results on Tuesday, February 20, 2024 , following the close of trading. Halozyme will host a conference call on Tuesday, February 20, 2024 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The conference call may be accessed live... Read More

SAN DIEGO , Jan. 29, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received European Commission (EC) approval for HYQVIA ® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE ® drug delivery technology as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with... Read More

VYVDURA® provides patients with option for self-administration SAN DIEGO , Jan. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for VYVDURA ® (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme's ENHANZE ® drug delivery technology for subcutaneous (SC) use for... Read More

SAN DIEGO , Jan. 16, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received U.S. Food and Drug Administration (FDA) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE® drug delivery technology for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of... Read More

Reduces treatment time by approximately 80% compared to standard intravenous (IV) infusion Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to IV infusion and is preferred by patients and healthcare practitioners 1 - 6 SAN DIEGO , Jan. 16, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC)... Read More

SAN DIEGO , Jan. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it will host an Investor Business Forum and Long-Term Outlook Call on Wednesday, January 17, 2024 at 5:30 a.m. PT / 8:30 a.m. ET . On the call, Dr. Helen Torley , President and Chief Executive Officer will be joined by Mark Snyder , Chief Legal Officer and Nicole LaBrosse , Chief Financial Officer to present... Read More

SAN DIEGO , Nov. 27, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follow: Event: Piper Sandler 35 th Annual Healthcare Conference Presenter: Nicole LaBrosse, Chief Financial Officer Format: Fireside Chat and... Read More

VYVGART® SC Now Approved for Subcutaneous Administration, Adding to the Already Approved IV Administration SAN DIEGO , Nov. 16, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received European Commission (EC) approval of VYVGART® SC (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE® for the treatment of generalized myasthenia gravis (gMG) in adult... Read More

Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted EPS of $0.61 and Non-GAAP Diluted EPS of $0.75 1 Maintained Revenue Guidance and Raised 2023 EBITDA Guidance to $430 - $445 million and Non-GAAP EPS Guidance to $2.70 - $2 .80 SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or... Read More

Acumen represents thirteenth license partner for ENHANZE ® Alzheimer's disease is a large and expanding market opportunity SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme's ENHANZE ® drug delivery technology, a proprietary recombinant human... Read More

SAN DIEGO , Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, November 6, 2023 , following the close of trading. Halozyme will host a conference call on Monday, November 6, 2023 at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The conference call may be accessed live with... Read More

BMS in discussions with health authorities regarding next steps for submission and approval of subcutaneous nivolumab in multiple indications SAN DIEGO , Oct. 19, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from the Phase 3 CheckMate-67T trial evaluating a subcutaneous (SC) formulation of Opdivo (nivolumab) with... Read More

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume auto-injector SAN DIEGO , Oct. 16, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative... Read More

SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follow: Event: 2023 Wells Fargo Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Thursday,... Read More

First subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain Tecentriq ® subcutaneous formulation with ENHANZE ® reduces treatment time to seven minutes compared to 30-60 minutes for standard intravenous infusion SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the approval of Roche's Tecentriq ® SC (atezolizumab), using... Read More

Revenue Increased 45% YOY to $221.0 million ; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.74 1 Royalty Revenue Increased 31% YOY to Record $111.7 million Raised 2023 Non-GAAP Diluted EPS Guidance to $2.65 - $2.75 Updated Revenue Guidance to $825 - $845 million , Representing 25-28% YOY Growth, and EBITDA Guidance to $420 - $440 million , Representing >30% YOY Growth 1 SAN DIEGO , Aug. 8, 2023 /PRNewswire/ --... Read More

SAN DIEGO , July 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results on Tuesday, August 8, 2023 , following the close of trading. Halozyme will host a conference call on Tuesday, August 8, 2023 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The conference call may be accessed live with pre-registration... Read More

SAN DIEGO , July 17, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx reported positive topline data from the ADHERE study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) with ENHANZE® in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint (p=0.000039) demonstrating a significantly lower risk of... Read More

SAN DIEGO , July 13, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche's Phase 3 OCARINA II trial evaluating OCREVUS ® (ocrelizumab) with ENHANZE ® as a twice a year 10-minute subcutaneous (SC) injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis (MS) or primary progressive MS (RMS or PPMS). OCREVUS subcutaneous... Read More

VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) SAN DIEGO , June 20, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE® for subcutaneous (SC) use for the treatment of... Read More

SAN DIEGO , June 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 , at 8 a.m. PT / 11 a.m. ET . A live webcast of the presentation will be available on the Investor Relations section of the Company's website. Replays... Read More

Revenue Increased 38% YOY to $162.1 million ; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue Increased 43% YOY to $99.6 million Reiterating 2023 Revenue Guidance of $815 - $845 million , Representing 23-28% YOY Growth; EBITDA of $415 - $440 million , Representing >30% YOY Growth 1 SAN DIEGO , May 9, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO)... Read More

SAN DIEGO , May 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow: Event: BofA Securities 2023 Health Care Conference Format: Corporate Presentation and 1x1 Meetings Presentation Date:... Read More

SAN DIEGO , April 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating results on Tuesday, May 9, 2023 , following the close of trading. Halozyme will host a conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The conference call may be accessed live with pre-registration via... Read More

Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPRO ® and SC through at least 2030 Reiterates 2023 Revenue Guidance of $815 million to $845 million and Royalty Revenue of $445 million to $455 million SAN DIEGO , March 15, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today provides an update on a decision by the Opposition Division of the European Patent... Read More

Fourth Quarter Revenue Increased 78% YOY to $181 million ; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.48 1 Full Year 2022 Revenue Increased 49% YOY to $660.1 million ; GAAP Diluted Earnings per Share of $1.44 and Non-GAAP Diluted Earnings per Share of $2.21 1 Record Fourth Quarter Royalty Revenue Increased 69% YOY to $106.0 million ; Record Full Year Royalty Revenue Increased 77%... Read More

SAN DIEGO , Feb. 7, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2022 financial and operating results on Tuesday, February 21, 2023 , following the close of trading. Halozyme will host a conference call on Tuesday, February 21, 2023 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The conference call may be accessed live... Read More

SAN DIEGO , Feb. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience as a financial executive with significant leadership roles in the biopharmaceutical industry. "We are delighted to welcome a leader with Barbara's extensive biopharmaceutical industry and finance... Read More

SAN DIEGO , Jan. 11, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it has elected to redeem on March 17, 2023 (the "Redemption Date") all of its outstanding 1.25% convertible senior notes due 2024 (the "Notes") pursuant to Section 4.03 of the Indenture, dated as of November 18, 2019 (the "Indenture"), between Halozyme and The Bank of New York Mellon Trust Company, N.A., as... Read More

2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from Royalties Projected to Grow by >20% to $445 to $455 Million 2023 EBITDA Projected to Grow by >30% Year-Over-Year to $415 to $440 Million 2023 Non-GAAP Diluted EPS Guidance of $2.50 to $2 .65 SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced its... Read More

SAN DIEGO , Jan. 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:45 p.m. PT / 6:45 p.m. ET . A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website.... Read More